A History of Ibogaine

The forest, the root, the ceremony

Long before ibogaine had a name, the root bark of the iboga shrub — Tabernanthe iboga — was known to the peoples of what is now Gabon, Cameroon, and the Congo Basin. Forager tribes discovered its psychoactive properties and passed that knowledge to the Bwiti, a spiritual tradition that would become the plant's primary cultural custodian.

In Bwiti initiation ceremonies, iboga root bark is consumed in large quantities — enough to induce a visionary state lasting 24 hours or more. This is not recreational use. It is a ritual undertaken once in a lifetime, or rarely, as a passage into adulthood or a deeper stage of spiritual life. The experience is considered a meeting with ancestors, a confrontation with one's own nature, and a death-and-rebirth of the self.

The ceremony is conducted by a specialist — a nganga — who guides initiates through the experience and interprets what arises. The setting, the preparation, the musical accompaniment, and the community context are all considered integral to what the plant does. The idea that ibogaine could be extracted, standardised, and administered in a clinical setting — stripped of all this — is something the Bwiti tradition views with a mixture of curiosity and concern that is worth holding in mind throughout this history.

The Western encounter — 19th century

The first documented Western accounts of iboga use came from French and Belgian explorers in Gabon during the 19th century. French naval physician Marie-Théophile Griffon du Bellay was among the earliest to observe and write about the plant's use in ceremony. His accounts, and those of contemporaries, described the visionary and stimulant effects of the root with a mixture of fascination and colonial condescension typical of the era.

The first formal botanical description of Tabernanthe iboga was published in 1889. Ibogaine itself was first chemically isolated from the plant in 1901, independently by two pairs of researchers — Dybowski and Landrin, and Haller and Heckel — working with plant samples collected in Gabon. The compound was given its name and its structure was later confirmed by X-ray crystallography in 1960.

Stimulant, schedule, synthesis — 1900 to 1960

In the decades following ibogaine's isolation, European interest in the compound focused on its stimulant properties at low doses — quite different from the visionary effects of the ceremonial doses used in Gabon. In France, an extract of the related plant Tabernanthe manii was marketed under the name Lambarène from the 1930s through the 1960s.

Lambarène tablets contained low doses of ibogaine — roughly 4 to 8 mg per tablet — and were promoted as a mental and physical tonic. The drug found a following among athletes in post-war France, where stimulant use in sport was neither unusual nor prohibited. It was, by today's standards, a relatively mild preparation; nothing in its commercial presentation hinted at the complex and controversial substance it would become.

In 1966, France withdrew Lambarène from the market as ibogaine-containing products became illegal. The same year, G. Büchi completed the first total chemical synthesis of ibogaine — confirming the compound's structure and opening the door to laboratory production independent of the plant.

1962 — The accidental discovery that changed everything

In the spring of 1962, a 19-year-old heroin addict named Howard Lotsof took ibogaine for the first time in New York City. He was not looking for a treatment for his addiction. He was looking for a new psychedelic experience. What he found was something he had not expected and could not have predicted.

After the experience, Lotsof noticed that his craving for heroin had vanished and his withdrawal symptoms had not appeared. He gave ibogaine to five friends, all of whom were also heroin addicts. Three of the five reported the same effect — a dramatic reduction in craving and the absence of expected withdrawal. For Lotsof, this was not anecdote. It was a signal.

Lotsof's patent, granted in 1985, covered the use of ibogaine in treating opioid dependence. It was a remarkable document — a former addict holding intellectual property on a Schedule I substance, arguing to governments and institutions that what he had experienced deserved serious scientific investigation.

The underground years — 1970s to 1990s

As ibogaine became a Schedule I substance in the United States in the late 1960s — classified alongside heroin and LSD as having no accepted medical use — formal research became nearly impossible. But the word had spread, and people seeking treatment for addiction began finding their way to ibogaine through informal networks.

In 1981, a European manufacturer produced a batch of iboga extract. A man named Carl Waltenburg purchased the entire stock and distributed it under the name "Indra extract," using it to treat heroin addicts in the community of Christiania, Copenhagen. The operation was clandestine, unregulated, and in the eyes of most medical authorities, deeply problematic — and yet it represented the only available option for many people for whom conventional treatment had failed.

In 1992, Eric Taub brought ibogaine treatment to an offshore location near the United States, where he began providing it to patients. Lex Kogan joined him in systematising the approach. Together they established medically monitored treatment clinics in several countries — Mexico, the Netherlands, South Africa — that became the template for the treatment clinic model that exists today. These clinics operated in legal gray areas, as many still do.

The NIDA trials — and their abrupt end

In the early 1990s, the National Institute on Drug Abuse (NIDA) began funding clinical studies of ibogaine in the United States — a significant development that suggested the substance might finally receive the rigorous scientific evaluation it needed. A clinical study was conducted in 1993. Then, in 1995, the project was terminated following the unexpected death of a female participant.

The death ended formal US government-funded ibogaine research for years. The scientific community drew back. The underground continued.

The research era — 2000s and 2010s

Through the 2000s and into the 2010s, ibogaine research resumed — slowly and largely outside the United States. Observational studies, case series, and small clinical investigations accumulated, painting a consistent if incomplete picture: ibogaine appeared to reduce opioid withdrawal and craving in ways that existing treatments could not replicate, but it carried serious cardiac risks that demanded careful management.

The Global Ibogaine Therapy Alliance published its clinical guidelines in 2015 — the first attempt to codify what responsible ibogaine administration should look like, drawing on the accumulated experience of clinicians who had been working with the substance for decades. The guidelines set minimum standards for screening, monitoring, and aftercare that gave the field a professional framework, even as it remained largely outside mainstream medicine.

Systematic reviews in 2022 and 2023 surveyed the existing evidence and arrived at a similar conclusion: the anti-addictive signal was real and consistent enough to warrant serious investigation, but the evidence base remained too limited — and the safety risks too significant — to support routine clinical use without further rigorous trials. Only two randomised controlled trials had been completed. That number has not changed.

The mainstream moment — 2020s

The shift from fringe to mainstream accelerated sharply in the early 2020s, driven by a confluence of factors: the worsening opioid crisis in the United States, growing public interest in psychedelic medicine following the success of psilocybin and MDMA research, and a series of high-profile accounts from military veterans who reported dramatic improvement in PTSD symptoms after ibogaine treatment.

The 2023 Stanford University study of Special Operations veterans — conducted at a supervised clinic in Mexico — generated widespread media coverage and carried particular political weight. Veterans' advocates brought ibogaine to the attention of elected officials who had shown little prior interest in psychedelic research. Former Texas Governor Rick Perry became a prominent supporter. In January 2025, Perry appeared on The Joe Rogan Experience alongside W. Bryan Hubbard to discuss ibogaine's potential — reaching an audience of millions and cementing the substance's place in mainstream public discourse.

Key milestones at a glance

Where this history leads next depends on whether the clinical trials now beginning in Texas and elsewhere can generate the evidence needed to satisfy regulatory standards — and whether the political will that has emerged survives long enough to act on it. The story is not finished.